Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
| ▸ | GPR55 | Q9Y2T6 | 4/20 | 0.36 |
| ▸ | CNR2 | P34972 | 2/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.33 |
| ▸ | TOP2A | P11388 | 1/20 | 0.33 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.33 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.32 |
| ▸ | CTRC | Q99895 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 3/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6292710 | 0.88 | MMP13 (0.43) | MMP13PDE3BPDE3AMEN1KMT2A | |
| SCHEMBL6292732 | 0.85 | GPR55 (0.36) | MMP13GPR55CNR2CNR1PDE3B | |
| SCHEMBL6289351 | 0.80 | MMP13 (0.35) | MMP13GPR55CNR2CNR1MEN1 | |
| SCHEMBL6288743 | 0.78 | MMP13 (0.37) | MMP13PDE3BPDE3AMEN1KMT2A | |
| SCHEMBL6288706 | 0.78 | CNR2 (0.40) | GPR55CNR2CNR1MEN1KMT2A | |
| SCHEMBL6292111 | 0.77 | MMP13 (0.36) | MMP13GPR55CNR2CNR1MEN1 | |
| SCHEMBL6288785 | 0.77 | LMNA (0.47) | CNR2MEN1KMT2ABRD4RXFP1 | |
| SCHEMBL6289021 | 0.71 | MMP13 (0.35) | MMP13MEN1KMT2ATP53MAPT | |
| SCHEMBL6288761 | 0.71 | PDE3B (0.40) | MMP13GPR55CNR2PDE3BPDE3A | |
| SCHEMBL6289364 | 0.69 | MAPK14 (0.35) | MMP13PDE3BPDE3ARXFP1PLA2G7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6949651-B2 | Fused bicyclic metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2005-09-27 | — | — | US | disclosed |
| US-20040034054-A1 | Fused bicyclic metalloproteinase inhibitors | LINCOLN FOODSERVICE PRODUCTS INC. | 2004-02-19 | — | — | US | disclosed |
| WO-2004014375-A2 | FUSED BICYCLIC METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034054-A1 | Fused bicyclic metalloproteinase inhibitors | MMP9, MMP1, MMP2 | MMP13 9/4885GPR55 2874/4885CNR2 2917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.